At its core, it is about more than just funding. Beiersdorf wants to translate scientific breakthroughs into marketable skincare products more quickly. To this end, the fund invests in start-ups worldwide, from the early phase through to growth, and combines capital with access to research, development and global brand platforms. The direction is clear. Innovation increasingly arises where internal research meets external dynamics. Examples from the existing portfolio show the potential. Technologies from microbiome research have already been integrated into the company's own development and now characterise the innovation pipeline. At the same time, fields such as longevity, research and AI-supported drug development are moving centre stage. Sustainability also plays a central role. Investments in recycling technologies and bio-based ingredients are set to change the value chain in the long term. The move is a signal for the life sciences market. Competition in skincare is increasingly shifting towards science-based solutions. With the new fund, Beiersdorf is positioning itself as an active part of a global innovation ecosystem and is specifically accelerating the path from idea to application.
Press release of "Beiersdorf AG" dated 31 March 2026